Royal Bank of Canada Lowers ACADIA Pharmaceuticals (NASDAQ:ACAD) Price Target to $35.00
ACADIA Pharmaceuticals (NASDAQ:ACAD – Get Free Report) had its price objective decreased by investment analysts at Royal Bank of Canada from $36.00 to $35.00 in a research note issued on Wednesday, Benzinga reports. The firm currently has an “outperform” rating on the biopharmaceutical company’s stock. Royal Bank of Canada’s target price indicates a potential upside […]
More Stories
Merck & Co., Inc. (NYSE:MRK) Shares Acquired by Aviso Wealth Management
Aviso Wealth Management grew its stake in Merck & Co., Inc. (NYSE:MRK – Free Report) by 16.7% in the 3rd...
Jackson Hill Advisors LLC Cuts Stock Holdings in Alphabet Inc. (NASDAQ:GOOG)
Jackson Hill Advisors LLC lowered its position in Alphabet Inc. (NASDAQ:GOOG – Free Report) by 53.6% in the 3rd quarter,...
Capital City Trust Co. FL Acquires 1,631 Shares of Walmart Inc. (NYSE:WMT)
Capital City Trust Co. FL increased its holdings in shares of Walmart Inc. (NYSE:WMT – Free Report) by 2.0% in...
Cassaday & Co Wealth Management LLC Buys 748 Shares of Walmart Inc. (NYSE:WMT)
Cassaday & Co Wealth Management LLC raised its holdings in Walmart Inc. (NYSE:WMT – Free Report) by 3.0% during the...
Taurus Asset Management LLC Trims Stake in Bank of America Co. (NYSE:BAC)
Taurus Asset Management LLC lessened its position in Bank of America Co. (NYSE:BAC) by 4.6% in the third quarter, according...
OneAscent Wealth Management LLC Takes $647,000 Position in The Procter & Gamble Company (NYSE:PG)
OneAscent Wealth Management LLC purchased a new position in The Procter & Gamble Company (NYSE:PG – Free Report) during the...